Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases
Date:7/7/2009

with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Prevalence

Bone metastases, cancer cells that separate from tumors and migrate to bone tissue where they settle and grow, occur in more than 1.5 million people worldwide.(1) With improvements in cancer care, including earlier diagnosis and new treatment options, leading to increases in survival rates(2), the number of patients developing metastatic disease secondary to a primary cancer is increasing. Bone metastases are a significant problem for patients with certain types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 percent in breast and prostate cancer patients.

With bone metastases the growing cancer cells weaken and destroy the bone around the tumor. The damage the tumor has caused to the bone can result in a number of serious
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis
2. Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
3. Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
4. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
5. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
6. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
7. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
10. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
11. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 1Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 4Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 1Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3
...Company Planning to Initiate Phase 2 Trials in Col...Cancer in Q307 -, SOUTH SAN FRANCISCO, Calif., Jun...aceuticals, Inc. , a,biopharmaceutical company foc...s from an interim safety analysis of two Phase 1,d...ion platinum for,the potential first-line treatmen...
...ven year follow up of pivotal trial confirms that ...EL, Switzerland, June 4, 2007-A follow-up analysis...non-Hodgkin,s lymphoma,(NHL) who were treated with...) over seven years ago has revealed exciting resul...ase III study has shown,that over half (53%) of th...
Other Medicine Technology:Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 2MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 4
(Date:11/8/2009)...ewswire-USNewswire/ -- Tonight the House of Repres...erica Act, landmark health reform legislation that... affordable, stable and secure health care coverag...he insurance industry,s worst practices, would ext...eficit by $104 billion over ten years. Groups repr...
(Date:11/8/2009)...’s Health Network (MHN) urges military veter...those linked to exposure to chemicals, atomic agen...r cancer is one of those cancers that is two times...once smoked or currently smoke cigarettes. , ... 8, 2009 -- Men’s Health Network (MHN) kicke...
(Date:11/8/2009)...rk of Hispanic health advocates committed to achie...WASHINGTON, Nov. 7 "Ton... have heard the voice of America,s families by pas...ow the Senate must deliver, without delay, on the .... Jane L. Delgado, President and CEO of the Nation...
(Date:11/8/2009)...ewswire-USNewswire/ -- The following was released ... Insurrecta Nex. ,, Mr. Terry and his associat...eep child-killing by abortion out of any health ca...is a great first step to victory -- a touchdown in...g ahead of us. Our rejoicing must be tempered by r...
(Date:11/8/2009)... 8 March of Dimes hoste... to recognize prominent individuals who are celebr... models for March of Dimes commitment to improve t...s November Prematurity Awareness Month campaign, c...he fight for preemies! ,, (Photo: http://www....
Breaking Medicine News(10 mins):Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...arrow removal and injection of a hormone helps pro...ions in the body, it was reported by Yale School o...his could radically change the way patients are cu...ssor of orthopedics . , She said currently avail...
...shing Taste with Benefits of Noni, PROVO, Utah, F... HIRO(TM) Super Fruits Sparkling Black Currant, th...-drink noni-based beverage line. An all,natural be...ling Black Currant is the first of a new,category ...
... for,Disease Control and Prevention released resul...EMA travel trailers. On May 15, 2007, FEMA,Adminis...ee on Homeland,Security that "we have been told th...maldehyde exposure can range from,respiratory irri...
...detzki, has found a link between cell phone usage ... physician, epidemiologist and lecturer at Tel Avi...ently in the American Journal of Epidemiology, in ... Those who used a cell phone heavily on the side o...
...tion,s,largest pharmacy benefits management compan... General from 29 states resolving claims of,decept...bett said that the agreement was reached with,Care...required to significantly change,its business prac...
...e Next Before Final Version is,Voted On, BETHESDA...essions of "national need" will include occupation...oor is agreed to by the,Senate. AOTA staff worked ... floor of the House that occupational therapists,b...
Other Medicine News:Health News:Tahitian Noni International Expands HIRO(TM) Beverage Line With Super Fruits Sparkling Black Currant 2Health News:Thompson Demands Solution to Formaldehyde Trailer Crisis 2Health News:Cell phone-cancer link found by Tel Aviv University scientist 2Health News:Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark 2Health News:Pennsylvania Attorney General Corbett Announces Multi-State Settlement With Caremark 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2
...o-Surgery provides clip appliers in 10mm and 5mm s...iers provide precise clip placement., ,The ALLPOR...e preloaded, single-trigger instruments are design... a 5mm trocar, through a 5mm reducer cap in a larg...
...P-HS assay utilizes turbidimetric immunoassay meth...uring over the range of 0.2-28.0 mg/dL. This assay...to most clinical chemistry analyzers. The Wako CRP...ecision, linearity, correlation, and sensitivity. ...
LabDAQ3 Laboratory Information System
...e for laboratories to work more efficiently has ne...e solutions. With the COBAS INTEGRA® 400 plus,...ies, robotic handling of reaction cuvettes and imp...broad menu and ease-of-use required for true workl...
Medicine Products: